FDA New Drug and Biologic Approvals -- 2017 Year-in-Review

Mary L Windle, PharmD


January 11, 2018

In This Article

Vosevi (sofosbuvir/velpatasvir/voxilaprevir)


Re-treatment of hepatitis C virus (HCV) infection in adults with genotype 1, 2, 3, 4, 5, or 6 previously treated with an NS5A inhibitor-containing regimen. Also indicated for genotypes 1a or 3 in patients previously treated with a sofosbuvir-containing regimen without an NS5A inhibitor.


Voxilaprevir is new to the U.S. market.

Sofosbuvir: Inhibitor of HCV NS5B RNA-dependent polymerase; its inhibition, in turn, suppresses viral replication.

Velpatasvir: Pangenotypic HCV NS5A inhibitor; the NS5A protein is required for viral replication.

Voxilaprevir: Pangenotypic NS3/4A protease inhibitor, which is needed for proteolytic cleavage of the HCV-encoded polyprotein into mature forms and is essential for viral replication.


1 tablet (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg) PO once daily for 12 weeks.


Approval was based on two phase 3 clinical trials, POLARIS-1 and POLARIS-4 (n=728) in adults with chronic HCV infection without cirrhosis or with compensated cirrhosis. Results of both trials demonstrated a sustained viral response of 96-98% at 12 weeks following treatment in patients who received sofosbuvir/velpatasvir/voxilaprevir.


Bourlière M, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017 Jun 1;376(22):2134-46.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.